Good afternoon from STAT’s London outpost, with reporter Andrew Joseph here filling in for Mr. Pharmalot. As is so often the case these days, the STAT team is feeling a bit inundated with all the news, but we hope that good things await you too, on top of all the headlines.

In a highly unusual move, the U.S. Food and Drug Administration reapproved a GSK drug that stopped being sold more than 25 years ago, part of a push from the Trump administration to identify the causes of and potential treatments for autism, STAT writes . The drug, Wellcovorin, is a branded version of leucovorin, a generic drug that’s generally used to help tame other medicines’ side effects. The FDA said it had conducted a systematic analysis of research published between 2009 and 2024 and found that leucovorin was

See Full Page